Search Result

Results for "

NEKs

" in MedChemExpress (MCE) Product Catalog:

By Targets:	NEKs (42) AAK1 (2) Amyloid-β (2) Apoptosis (17) Aurora Kinase (2) Autophagy (1) Bcl-2 Family (1) CaMK (1) Caspase (4) CDK (5) Cyclin G-associated Kinase (GAK) (1) Discoidin Domain Receptor (1) DNA/RNA Synthesis (2) DYRK (1) EGFR (1) Ferroptosis (1) HDAC (1) Histone Demethylase (1) HOXA (1) Interleukin Related (7) LIM Kinase (LIMK) (2) MDM-2/p53 (1) Mitosis (2) Molecular Glues (8) NF-κB (2) NOD-like Receptor (NLR) (16) PI3K (1) Polo-like Kinase (PLK) (1) PPAR (1) PROTACs (2) Pyroptosis (3) Reference Standards (3) Ribosomal S6 Kinase (RSK) (1) Salt-inducible Kinase (SIK) (2) Ser/Thr Protease (1) Small Interfering RNA (siRNA) (27) SnRK (1) STAT (1) TLK (1) ULK (1) Vasopressin Receptor (1) Wee1 (1)
By Research Areas:	Cancer (35) Cardiovascular Disease (5) Inflammation/Immunology (19) Metabolic Disease (4) Neurological Disease (9)
Click Chemistry:	Alkynes (3)
Oligonucleotides:	Rat Pre-designed siRNA Sets (8) Mouse Pre-designed siRNA Sets (8) Human Pre-designed siRNA Sets (11) siRNAs (27)

Inhibitors & Agonists

Natural
Products

Click Chemistry

Oligonucleotides

Targets Recommended: NEKs

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-N3005

Britannin 1 Publications Verification	Apoptosis Autophagy NOD-like Receptor (NLR) Pyroptosis	Inflammation/Immunology Cancer
Britannin is an NLRP3 inhibitor with an IC₅₀ of 3.630 μM, exhibiting anti-inflammatory activity. Britannin inhibits the activation and assembly of the NLRP3 inflammasome by blocking the interaction between NLRP3 and *NEK7*. Additionally, Britannin demonstrates antitumor activity by inhibiting the proliferation of tumor cells through blocking the interaction between HIF-1α and Myc, thereby suppressing PD-L1 expression and enhancing cytotoxic T lymphocyte activity. Britannin can also induce apoptosis and autophagy in liver cancer cells by activating ROS-regulated AMPK. Britannin holds promise for research in the fields of anti-inflammatory and antitumor therapeutics .

HY-N0373

Licochalcone B 10+ Cited Publications	Amyloid-β Apoptosis NOD-like Receptor (NLR)	Neurological Disease
Licochalcone B is an extract from the root of Glycyrrhiza uralensis. Licochalcone B inhibits amyloid β (₄₂) self-aggregation (IC₅₀=2.16 μM) and disaggregate pre-formed Aβ₄₂ fibrils, reduce metal-induced Aβ₄₂ aggregation through chelating metal ionsLicochalcone B inhibits phosphorylation of NF-κB p65 in LPS signaling pathway. Licochalcone B inhibits growth and induces apoptosis of NSCLC cells. Licochalcone B specifically inhibits the NLRP3 inflammasome by disrupting NEK7‐NLRP3 interaction .

HY-159520

Ofirnoflastum Ofirnoflast; HT-6184	NEKs NOD-like Receptor (NLR) Caspase Apoptosis Pyroptosis NF-κB	Cardiovascular Disease Inflammation/Immunology Cancer
Ofirnoflastum (Ofirnoflast) is an orally active first-in-class allosteric *NEK7* inhibitor with an IC₅₀ of 46 nM. Ofirnoflastum binds an allosteric site adjacent to NEK7’s ATP-binding pocket, induces conformational shifts, disrupts NEK7-NLRP3 binding, blocks NLRP3 inflammasome assembly, spares NEK7’s physiological functions, and suppresses caspase-1, caspase-8, NF-κB, and TNF activity. Ofirnoflastum reduces pro-inflammatory cytokine production, suppresses ASC specks, IL-1β release, pyroptotic cell death, and leukemic burden, induces apoptosis and erythroid differentiation, restores hematopoiesis, and improves outcomes in colitis models. Ofirnoflastum can be used for the research of myelodysplastic syndromes, chronic myelomonocytic leukemia, and acute myeloid leukemia .

HY-172162

LC-04-045	Molecular Glues NEKs Interleukin Related	Inflammation/Immunology Cancer
LC-04-045 is a selective NIMA-related kinase 7 (NEK7) molecular glue degrader. LC-04-045 induces NEK7 degradation via the CRBN-based ubiquitin-proteasome system, dependent on the glycine 57-containing degron motif. LC-04-045 inhibits secretion of downstream cytokines IL-1β and IL-18. LC-04-045 can be used for the research of lymphoblastic leukemia .

HY-122639

ZINC05007751 3 Publications Verification	NEKs	Cancer
ZINC05007751 is a potent NIMA-related kinase *NEK6* inhibitor with an IC₅₀ of 3.4 μM. ZINC05007751 shows antiproliferative activity against a panel of human cancer cell lines, and displays a synergistic effect with Cisplatin and Paclitaxel in a BRCA2 mutated ovarian cancer cell line. ZINC05007751 is very selective against NEK1 and NEK6 with no significant activity was observed against NEK2, NEK7, and NEK9 .

HY-176860

NEK7 degrader-1	Molecular Glues NEKs NOD-like Receptor (NLR) Caspase Interleukin Related	Cardiovascular Disease Neurological Disease Inflammation/Immunology
NEK7 degrader-1 is a NEK7 molecular glue degrader with a DC₅₀ of 9  nM. NEK7 degrader-1 dose-dependently inhibits caspase-1 activity and IL-Ιβ release in macrophages in response to NLRP3 inflammasome activation. NEK7 degrader-1 can be used for autoinflammatory and autoimmune disorders like multiple sclerosis, neurodegeneraive diseases like Alzheimer's disease and cardiovascular and melabolic disorders like pericarditis and Type 2 diabetes research .

HY-120356A

T-1101 tosylate 1 Publications Verification TAI-95 tosylate	NEKs Apoptosis	Cancer
T-1101 tosylate (TAI-95 tosylate) is the tosylate salt form of T-1101 (HY-120356). T-1101 tosylate is an orally active inhibitor for mitose regulating highly expressed oncoprotein 1 (Hec1). T-1101 tosylate blocks the interaction between Hec1 and *NEK2, exhibits cytotoxicity in human liver cancer cells with GI₅₀* of 15-70 nM. T-1101 tosylate induces apoptosis in Huh-7. T-1101 tosylate exhibits antitumor efficacy in mouse models .

HY-153916

TCRS-417 1 Publications Verification T417	HOXA DNA/RNA Synthesis NEKs	Neurological Disease Inflammation/Immunology Cancer
TCRS-417 (T417) is a small-molecular inhibitor for PBX1. TCRS-417 can directly block PBX1-binding to DNA (IC₅₀ = 6.58 μM), and affects PBX1 transcription. TCRS-417 is able to hammer out the stemness traits of Carboplatin (HY-17393)-resistant (CR) cells to revert to a differentiated status through tacking PBX1 signaling cascade. TCRS-417 significantly suppresses self-renewal and proliferation of cancer cells expressing high levels of PBX1. TCRS-417 can decrease the mRNA levels of FOXM1, *NEK2, and E2F2* in cancer cell lines. TCRS-417 is selectively toxic against chr1q-amp myeloma and solid tumor cells .

HY-144425

BSc5367	NEKs	Inflammation/Immunology
BSc5367 is a potent *Nek1* inhibitor with an IC₅₀ of 11.5 nM. NIMA-related protein kinase Nek1 is crucially involved in cell cycle regulation, DNA repair and microtubule regulation and dysfunctions of Nek1 play key roles in amyotrophic lateral sclerosis (ALS), polycystic kidney disease (PKD) and several types of radiotherapy resistant cancer .

HY-16660

INH1 IBT13131	NEKs Apoptosis	Cancer
INH1 specifically disrupts the Hec1/Nek2 interaction via direct Hec1 binding. INH1 shows promising cancer inhibition activity both in vitro and in vivo .

HY-W158030

2-Guanidinobezimidazole 2GBI	NOD-like Receptor (NLR) Vasopressin Receptor	Cardiovascular Disease Neurological Disease Cancer
2-Guanidinobezimidazole (2GBI) is a NLRP3 agonist with a K_D of 1.29 μM and a selective state-dependent HVCN1 blocker. 2-Guanidinobezimidazole directly binds NLRP3’s LRR domain, enhances NLRP3-ASC and *NLRP3-NEK7* interactions, and drives NLRP3 inflammasome activation. 2-Guanidinobezimidazole can be used for the research of LLC lung carcinoma, B16F10 melanoma and ischemic stroke .

HY-116423

JH295	NEKs	Cancer
JH295 is a potent, irreversible and selective NIMA-related kinase 2 (Nek2) inhibitor with an IC₅₀ of 770 nM. JH295 inhibits cellular *Nek2* via alkylation of Cys22. JH295 is inactive against the mitotic kinases, Cdk1, Aurora B or Plk1, and does not perturb bipolar spindle assembly or the spindle assembly checkpoint . JH295 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-101029

MBM-55	NEKs Apoptosis	Cancer
MBM-55 is a potent NIMA-related kinase 2 (Nek2) inhibitor with an IC₅₀ of 1 nM. MBM-55 shows a 20-fold or greater selectivity in most kinases with the exception of RSK1 (IC₅₀=5.4 nM) and DYRK1a (IC₅₀=6.5 nM). MBM-55 effectively inhibits the proliferation of cancer cells by inducing cell cycle arrest and apoptosis. MBM-55 shows antitumor activities, and no obvious toxicity to mice .

HY-117154

INH154 3 Publications Verification	NEKs	Cancer
INH154 is a highly potent inhibitor for Nek2 and Hec1 binding (INH), with IC₅₀s of 200 nM and 120 nM for INH in Hela and MB468 cells.

HY-156437

NBI-961	Apoptosis Ser/Thr Protease NEKs Mitosis	Cancer
NBI-961 is a potent *NEK2* inhibitor that inhibits proteasomal degradation. NBI-961 induces G2/mitosis arrest and apoptosis in diffuse large B cell lymphoma (DLBCL) cells .

HY-173154B

NK7-902 diTFA	Molecular Glues NEKs NOD-like Receptor (NLR) Interleukin Related	Inflammation/Immunology
NK7-902 diTFA is a selective and orally active CRBN-dependent *NEK7* molecular glue degrader with K_d values of 1.5 and 2.6 μM for hNEK7 and mNEK7. NK7-902 diTFA fully degrades NEK7 in human primary monocytes and whole blood but only partially inhibits NLRP3-dependent IL-1β production. NK7-902 diTFA shows activity in murine systems and induces a profound and long-lasting NEK7 degradation but only transiently blocks NLRP3 inflammasome activation. NK7-902 diTFA can be used for the research of inflammation, such as cryopyrin-associated periodic syndromes .

HY-176463

Nek2/Hec1-IN-3	NEKs	Cancer
Nek2/Hec1-IN-3 (Compound 11-28) is a *Hec1/Nek2* interaction inhibitor. Nek2/Hec1-IN-3 disrupts Nek2/Hec1 binding and can be used for research of neoplastic diseases .

HY-100541

INH6	NEKs Apoptosis	Cancer
INH6 is a potent *Nek2/Hec1* inhibitor; inhibits the growth of HeLa cells with an IC₅₀ of 2.4 μM.

HY-174270

NLRP3-IN-79	NOD-like Receptor (NLR) Interleukin Related NEKs	Inflammation/Immunology
NLRP3-IN-79 is an orally active NLRP3 inhibitor. NLRP3-IN-79 inhibits NLRP3 inflammasome with an IC₅₀ of 10.69 nM. NLRP3-IN-79 blocks NLRP3 inflammasome assembly by directly binding to NLRP3 and disrupting the *NEK7-NLRP3* interaction. NLRP3-IN-79 can be used for the study of NLRP3-driven diseases model, including systemic inflammation, peritonitis, and colitis .

HY-163358

SLC3037 1 Publications Verification	NOD-like Receptor (NLR) NEKs	Cardiovascular Disease Neurological Disease Inflammation/Immunology
SLC3037 is a NLRP3 inhibitor which blocks NLRP3 from binding to *NEK7* or oligomerization, inhibiting inflammasome caused by MSU and other inflammasome activators. SLC3037 can be used for research of gout, cardiovascular diseases, metabolic syndrome or neurodegenerative diseases .

HY-148062

RSS0680	PROTACs CDK AAK1 Cyclin G-associated Kinase (GAK) Salt-inducible Kinase (SIK) LIM Kinase (LIMK) Wee1 SnRK	Others
RSS0680 is a small noncoding RNA (sRNA) targeting the mRNA ribosome binding site (RBS) and a PROTAC with protein kinase degradation activity (Pink: FLT3-IN-17 (HY-148070); Black: Linker (HY-W041970); Blue: E3 ligase Ligand (HY-112078)). RSS0680 competitively binds to RBS through the conserved CCUCCUCCC anti-Shine-Dalgarno (aSD) sequence and inhibits the translation initiation of target genes. RSS0680 can interact with the DUF1127 protein CcaF1, regulate its own stability and participate in bacterial oxidative stress defense, enhancing the host's resistance to heat shock and oxidative damage by affecting pathways such as C1 metabolism and pyruvate dehydrogenase complex. RSS0680 degrades AAK1, CDK1, CDK16, CDK2, CDK4, CDK6, EIF2AK4, GAK, LATSl, LIMK2, MAPK6, MAPKAPK5, MARK2, MARK4, MKNK2, *NEK9, RPS6KB1, SIK2, SNRK, STK17A, STK17B, STK35, and WEEl*. RSS0680 can be used to study diseases or disorders mediated by aberrant kinase activity and regulatory mechanisms of noncoding RNAs in α-proteobacteria[1][2].

HY-103646

CK7	NEKs CDK	Others
CK7, a Cdk2/9 inhibitor, can be used for the synthesis of Nek1 inhibitor BSc5231 and BSc5367 .

HY-W599279

ABS-752	Molecular Glues NEKs	Cancer
ABS-752 is a potent and orally active GSPT1 and *NEK7* molecular glue degrader. ABS-752 shows cytotoxicity. ABS-752 decreases the protein expression of GSPT1 and SALL4, NEK7. ABS-752 is a prodrug activated by the monoamine oxidase, VAP-1, to an aldehyde intermediate and subsequently to the active molecule, ABT-002 (HY-175283). ABS-752 has the potential for the research of hepatocellular carcinoma .

HY-117884

(Rac)-CCT 250863	Apoptosis	Cancer
(Rac)-CCT 250863 (compound rac-21) is a selective and reversible NEK 2 inhibitor with an IC₅₀ of 0.073 µM. (Rac)-CCT 250863 shows good effects of inducing cell cycle arrest and also can antiproliferative in cells (Pomalidomide sensitive/resistant). (Rac)-CCT 250863 induces apoptosis when combines with Pomalidomide .

HY-101030A

MBM-17S	NEKs Apoptosis	Cancer
MBM-17S is a potent NIMA-related kinase 2 (Nek2) inhibitor, with an IC₅₀ of 3 nM. MBM-17S effectively inhibits the proliferation of cancer cells by inducing cell cycle arrest and apoptosis. MBM-17S shows antitumor activities, and no obvious toxicity to mice .

HY-148063

DB0614	PROTACs AAK1 Aurora Kinase CaMK CDK Ferroptosis Salt-inducible Kinase (SIK) LIM Kinase (LIMK) ULK	Metabolic Disease
DB0614 is a PROTAC based on Cereblon ligand, which is a selective and potent targeted protein degrader of *NEK9* inhibitor. DB0614 can degrade ABL1, ABL2, BLK, CDK11B, CDK4, CSK, EPHA3, FER, GAK, LIMK1, MAP3K20, MAP4K1, MAP4K2, MAP4K3, MAP4K5, MAPK14, MAPK7, MAPK8, MAPK9, MAPKAPK2, MAPKAPK3, NLK, PDIK1L, PTK2B, RIPK1, RPS6KA1, RPS6KA3, SIK2, SIK3, STK35, TNK2 and ULK1. DB0614 can be used for research of disease or disorder mediated by aberrant kinase activity .(Blue: Thalidomide-4-OH (HY-103596), Black: linker, Pink: FLT3-IN-17 (HY-148070))

HY-168737

NEK7-IN-2	NOD-like Receptor (NLR) NEKs	Inflammation/Immunology
NEK7-IN-2 (compound 23) is a potent inhibitor of *NLRP3-NEK7* interaction. NEK7-IN-2 can enhance the thermal stability of NEK7 and regulatie NLRP3 inflammasome assembly. NEK7-IN-2 inhibits IL-1β releases .

HY-169933

NEK7-IN-1	NEKs	Inflammation/Immunology Cancer
NEK7-IN-1 (Compound I-15) is the inhibitor for NIMA-related kinase 7 *NEK7* with IC₅₀ <100 nM. NEK7-IN-1 inhibits the IL-1β release with IC₅₀ <50 nM .

HY-177433

NEK7 degrader-4	Molecular Glues NEKs	Cardiovascular Disease Neurological Disease Metabolic Disease Inflammation/Immunology
NEK7 degrader-4 is a NEK7 molecular glue degrader with a DC₅₀ of 9  nM. NEK7 degrader-4 can be used for autoinflammatory and autoimmune disorders like multiple sclerosis, neurodegeneraive diseases like Alzheimer's disease and cardiovascular and melabolic disorders like pericarditis and Type 2 diabetes research .

HY-137046

Nek2-IN-4	NEKs	Cancer
Nek2-IN-4 is a potent *NEK2* inhibitor with an IC₅₀ value of 15 nM. Nek2-IN-4 inhibits cell proliferation. Nek2-IN-4 has the potential for the research of pancreatic cancer .

HY-120330

Nek2-IN-5	NEKs Mitosis	Cancer
Nek2-IN-5 (compound 6) is a potent and irreversible *Nek2* ((Never in mitosis gene a)-related kinase 2) inhibitior . Nek2-IN-5 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-177559

NEK7 degrader-2	NEKs Interleukin Related NOD-like Receptor (NLR)	Inflammation/Immunology
NEK7 degrader-2 (Compound 25) is a *NEK7* degrader. NEK7 degrader-2 shows dose-dependent *NEK7* degradation ability in human PBMC-derived macrophages. NEK7 degrader-2 reduce the release level of pro-inflammatory cytokines IL-1β induced by NLRP3 inflammasome activation. NEK7 degrader-2 can be used for the study of inflammatory diseases .

HY-175283

ABT-002	Molecular Glues NEKs	Cancer
ABT-002 is a molecular glue degrader targeting GSPT1 and *NEK7*. ABT-002 is the active metabolite of ABS-752 (HY-W599279). ABT-002 is promising for research of hepatocellular carcinoma (HCC) .

HY-101030

MBM-17	NEKs Apoptosis	Cancer
MBM-17 is a potent NIMA-related kinase 2 (Nek2) inhibitor with an IC₅₀ of 3 nM. It effectively inhibits the proliferation of cancer cells by inducing cell cycle arrest and apoptosis. MBM-55 shows antitumor activities, and no obvious toxicity to mice .

HY-150046

Nek2-IN-6	NEKs	Cancer
Nek2-IN-6 (Compound 28e) is a potent never in mitosis (NIMA) related kinase 2 (Nek2) inhibitor .

HY-163756

NLRP3-IN-43	NOD-like Receptor (NLR)	Inflammation/Immunology
NLRP3-IN-43 (compound II-8) is a poteny inhibitor of NLRP3 inflammasome activation that binds to the LRR domain, and disrupts *NLRP3-NEK7* interaction .

HY-116423A

JH295 hydrate	NEKs	Cancer
JH295 hydrate is a potent, irreversible and selective NIMA-related kinase 2 (Nek2) inhibitor with an IC₅₀ of 770 nM. JH295 hydrate inhibits cellular *Nek2* via alkylation of Cys22. JH295 hydrate is inactive against the mitotic kinases, Cdk1, Aurora B or Plk1, and does not perturb bipolar spindle assembly or the spindle assembly checkpoint . JH295 (hydrate) is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-149213

LSD1/TLK1-IN-1 J54; J3-54	Histone Demethylase TLK	Cancer
LSD1/TLK1-IN-1 is an orally active LSD1, TLK1, TLK2, TTK inhibitor with an LSD1 IC₅₀ of 0.247 μM. LSD1/TLK1-IN-1 suppresses phosphorylation of Nek1 at T141 and Rad9 at S328, abrogates the TLK1>Nek1>ATR>Chk1 axis, protects H3K4me1/2 from demethylation, and does not affect LSD2, MAO-A, or MAO-B. LSD1/TLK1-IN-1 induces apoptosis, bypasses cell-cycle arrest, suppresses tumor growth, acts as a weak D4R antagonist, downregulates PD-L1 expression, enhances T-cell killing response, inhibits gastric cancer cell proliferation, shows minimal toxicity, and has no significant effect on normal prostate cells. LSD1/TLK1-IN-1 can be used for the research of prostate cancer and gastric cancer .

HY-120356

T-1101 TAI-95	Apoptosis NEKs	Cancer
T-1101 (TAI-95) is an orally active inhibitor for mitose regulating highly expressed oncoprotein 1 (Hec1). T-1101 blocks the interaction between Hec1 and *NEK2, exhibits cytotoxicity in human liver cancer cells with GI₅₀* of 15-70 nM. T-1101 induces apoptosis in Huh-7. T-1101 exhibits antitumor efficacy in mouse models .

HY-101029A

MBM-55S	NEKs Ribosomal S6 Kinase (RSK) DYRK Apoptosis	Cancer
MBM-55S is a potent NIMA-related kinase 2 (Nek2) inhibitor with an IC₅₀ of 1 nM. MBM-55S shows a 20-fold or greater selectivity in most kinases with the exception of RSK1 (IC₅₀=5.4 nM) and DYRK1a (IC₅₀=6.5 nM). MBM-55S effectively inhibits the proliferation of cancer cells by inducing cell cycle arrest and apoptosis. MBM-55S shows antitumor activities, and no obvious toxicity to mice .

HY-117398

HCI-2184	NEKs	Cancer
HCI-2184 is a *Nek2* inhibitor with an IC₅₀ of 39.90 nM. HCI-2184 significantly increases the effectiveness of Bortezomib (HY-10227) in inhibiting proteasome activity .

HY-153749

Nek2/Hec1-IN-2	NEKs	Cancer
Nek2/Hec1-IN-2 (Compound 14) is an inhibitor of *Nek2/Hec1. Nek*2/Hec1-IN-2 inhibits cancer cell proliferation with IC₅₀ >25 μM .

HY-RS09198

NEK7 Human Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
NEK7 Human Pre-designed siRNA Set A contains three designed siRNAs for NEK7 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

NEK7 Human Pre-designed siRNA Set A NEK7 Human Pre-designed siRNA Set A

HY-RS27908

Nek9 Rat Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
Nek9 Rat Pre-designed siRNA Set A contains three designed siRNAs for Nek9 gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.

Nek9 Rat Pre-designed siRNA Set A Nek9 Rat Pre-designed siRNA Set A

HY-RS09199

NEK8 Human Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
NEK8 Human Pre-designed siRNA Set A contains three designed siRNAs for NEK8 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

NEK8 Human Pre-designed siRNA Set A NEK8 Human Pre-designed siRNA Set A

HY-RS23280

Nek2 Rat Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
Nek2 Rat Pre-designed siRNA Set A contains three designed siRNAs for Nek2 gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.

Nek2 Rat Pre-designed siRNA Set A Nek2 Rat Pre-designed siRNA Set A

HY-RS20063

Nek11 Mouse Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
Nek11 Mouse Pre-designed siRNA Set A contains three designed siRNAs for Nek11 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.

Nek11 Mouse Pre-designed siRNA Set A Nek11 Mouse Pre-designed siRNA Set A

HY-RS09192

NEK11 Human Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
NEK11 Human Pre-designed siRNA Set A contains three designed siRNAs for NEK11 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

NEK11 Human Pre-designed siRNA Set A NEK11 Human Pre-designed siRNA Set A

HY-RS18625

Nek1 Mouse Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
Nek1 Mouse Pre-designed siRNA Set A contains three designed siRNAs for Nek1 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.

Nek1 Mouse Pre-designed siRNA Set A Nek1 Mouse Pre-designed siRNA Set A

HY-RS09193

NEK2 Human Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
NEK2 Human Pre-designed siRNA Set A contains three designed siRNAs for NEK2 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

NEK2 Human Pre-designed siRNA Set A NEK2 Human Pre-designed siRNA Set A

Cat. No.	Product Name	Category	Target	Chemical Structure